Development of systemic chemotherapy starting from comparison with best supportive care: commentary on the INTEGRATE IIa phase III study.

Boku N

doi:10.21037/jgo-2025-aw-813

← 뒤로

Development of systemic chemotherapy starting from comparison with best supportive care: commentary on the INTEGRATE IIa phase III study.

사설/논평 0/5 보강

Journal of gastrointestinal oncology 2026 Vol.17(1) p. 41

Boku N

PMC 전문 ↗ 원문 ↗ DOI ↗ BibTeX ↓ RIS ↓

이 논문을 인용하기

BibTeX ↓ RIS ↓

APA Boku N (2026). Development of systemic chemotherapy starting from comparison with best supportive care: commentary on the INTEGRATE IIa phase III study.. Journal of gastrointestinal oncology, 17(1), 41. https://doi.org/10.21037/jgo-2025-aw-813

MLA Boku N. "Development of systemic chemotherapy starting from comparison with best supportive care: commentary on the INTEGRATE IIa phase III study.." Journal of gastrointestinal oncology, vol. 17, no. 1, 2026, pp. 41.

PMID 41816601

DOI 10.21037/jgo-2025-aw-813

같은 제1저자의 인용 많은 논문 (1)

Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 2024